Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial
Axi-cel plus atezolizumab had a manageable safety profile, with no new safety signals. Safety and efficacy of this combination were consistent with axi-cel monotherapy. Correlative analyses could inform with regard to which patients with LBCL may benefit from axi-cel and immune checkpoint inhibitor combinations.
Authors
- Frank Neumann (ORCID: https://orcid.org/0009-0001-0995-1537)
- Jerome Ritz (ORCID: https://orcid.org/0000-0001-5526-4669)
- Frederick Lundry Locke (ORCID: https://orcid.org/0000-0001-9063-6691)
- Jason R. Westin (ORCID: https://orcid.org/0000-0002-1824-2337)
- Alex Francisco Herrera (ORCID: https://orcid.org/0000-0002-9665-7415)
- Nikolay Grechko (ORCID: https://orcid.org/0009-0009-8090-9938)
- Caron Alyce Jacobson (ORCID: https://orcid.org/0000-0002-0180-0654)
- Daqin Mao (ORCID: https://orcid.org/0009-0007-2814-3969)
- Yohei Arihara (ORCID: https://orcid.org/0009-0001-7673-3724)
- Scott J. Rodig (ORCID: https://orcid.org/0000-0003-1761-9769)
- David B. Miklos (ORCID: https://orcid.org/0000-0003-0717-4305)
- Subing Cao (ORCID: https://orcid.org/0000-0003-2416-5742)
- Jennifer Sun (ORCID: https://orcid.org/0009-0008-8649-3817)
- Sabina Adhikary (ORCID: https://orcid.org/0009-0002-7578-6223)
Institutions
- City Of Hope National Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Sapporo Medical University (JP)
- Moffitt Cancer Center (US)
- City of Hope (US)
- Dana-Farber Cancer Institute (US)
- Aadi (United States) (US)
- Gilead Sciences (United States) (US)
- Kite (United States) (US)
- Dana-Farber Brigham Cancer Center (US)
- Stanford University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0602
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Gilead Sciences
- Dana-Farber Cancer Institute